Form 8-K

8-K — Harmony Biosciences Holdings, Inc.

Accession: 0001104659-26-056786

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0001802665

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — hrmy-20260507x8k.htm (Primary)

EX-99.1 (hrmy-20260507xex99d1.htm)

EX-99.2 (hrmy-20260507xex99d2.htm)

GRAPHIC (hrmy-20260507x8k001.jpg)

GRAPHIC (hrmy-20260507xex99d1001.jpg)

GRAPHIC (hrmy-20260507xex99d2g001.jpg)

GRAPHIC (hrmy-20260507xex99d2g002.jpg)

GRAPHIC (hrmy-20260507xex99d2g003.jpg)

GRAPHIC (hrmy-20260507xex99d2g004.jpg)

GRAPHIC (hrmy-20260507xex99d2g005.jpg)

GRAPHIC (hrmy-20260507xex99d2g006.jpg)

GRAPHIC (hrmy-20260507xex99d2g007.jpg)

GRAPHIC (hrmy-20260507xex99d2g008.jpg)

GRAPHIC (hrmy-20260507xex99d2g009.jpg)

GRAPHIC (hrmy-20260507xex99d2g010.jpg)

GRAPHIC (hrmy-20260507xex99d2g011.jpg)

GRAPHIC (hrmy-20260507xex99d2g012.jpg)

GRAPHIC (hrmy-20260507xex99d2g013.jpg)

GRAPHIC (hrmy-20260507xex99d2g014.jpg)

GRAPHIC (hrmy-20260507xex99d2g015.jpg)

GRAPHIC (hrmy-20260507xex99d2g016.jpg)

GRAPHIC (hrmy-20260507xex99d2g017.jpg)

GRAPHIC (hrmy-20260507xex99d2g018.jpg)

GRAPHIC (hrmy-20260507xex99d2g019.jpg)

GRAPHIC (hrmy-20260507xex99d2g020.jpg)

GRAPHIC (hrmy-20260507xex99d2g021.jpg)

GRAPHIC (hrmy-20260507xex99d2g022.jpg)

GRAPHIC (hrmy-20260507xex99d2g023.jpg)

GRAPHIC (hrmy-20260507xex99d2g024.jpg)

GRAPHIC (hrmy-20260507xex99d2g025.jpg)

GRAPHIC (hrmy-20260507xex99d2g026.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: hrmy-20260507x8k.htm · Sequence: 1

HARMONY BIOSCIENCES HOLDINGS, INC._May 7, 2026

0001802665false00018026652026-05-072026-05-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 7, 2026

HARMONY BIOSCIENCES HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39450

82-2279923

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

630 W. Germantown Pike, Suite 215

Plymouth Meeting, PA 19462

(Address of principal executive offices) (Zip Code)

(484) 539-9800

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Trading

Name of each exchange

Title of each class

Symbol(s)

on which registered

Common Stock, $0.00001 par value per share

HRMY

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On May 7, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 7.01. Regulation FD Disclosure.

On May 7, 2026, the Company posted an investor presentation to its website at ttps://ir.harmonybiosciences.com (the “Investor Presentation”). A copy of the Investor Presentation is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others.

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Investor Presentation speaks only as of the date of this Current Report on Form 8-K. The Company undertakes no duty or obligation to publicly update or revise the information contained in the Investor Presentation, although it may do so from time to time. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure. In addition, the exhibit furnished herewith contains statements intended as “forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in such exhibit. By furnishing the information contained in the Investor Presentation, the Company makes no admission as to the materiality of any information in the Investor Presentation that is required to be disclosed solely by reason of Regulation FD.

This Current Report on Form 8-K and its contents (including Exhibits 99.1 and 99.2) are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Note Regarding Forward-Looking Statements

Certain statements in this Current Report on Form 8-K constitute “forward-looking statements” within the meaning of the federal securities laws. These statements are based on management’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein including the risks discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the Securities and Exchange Commission (“SEC,”) on February 24, 2026, as well as other factors described from time to time in the Company’s filings with the SEC. Such forward-looking statements are made only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update or revise any forward-looking statement because of new information, future events or otherwise, except as otherwise required by law. If it does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description

99.1*

Press release issued by the Company, dated May 7, 2026.

99.2*

Investor Presentation, dated May 7, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

This Exhibit is furnished herewith and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except to the extent that Harmony Biosciences Holdings, Inc. specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HARMONY BIOSCIENCES HOLDINGS, INC.

Date: May 7, 2026

By:

/s/ Glenn Reicin

Glenn Reicin

Chief Financial Officer

EX-99.1

Filename: hrmy-20260507xex99d1.htm · Sequence: 2

Exhibit 99.1

HARMONY BIOSCIENCES REPORTS Q1 FINANCIAL RESULTS AND CONFIRMS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION; REINFORCES 2026 STRATEGIC PRIORITIES

WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion

Continue to Vigorously Protect WAKIX IP into 2030; Filed Suit Against AET Pharma/Sandoz Regarding Infringement of Amorphous Pitolisant Patent

Lifecycle Management Advancing with Pitolisant GR on Track for NDA Filing 2Q26, Pitolisant HD Phase 3 Data in 2027, and Recently Acquired Novel Amorphous Form of Pitolisant to Pursue Broader CNS Indications

Potential Best-in-Class Orexin-2 Agonist with BP-205; Phase 1 Clinical PK Data On Track for Mid-2026

Renewed Focus on Business Development Opportunities with Emphasis on Revenue Potential in the 2028 to 2032 Timeframe

Expansion of the Leadership Team with the Addition of New COO and CFO to Support Scale and Next Phase of Growth

Conference Call and Webcast Today at 8:30 a.m. ET

PLYMOUTH MEETING, Pa., May 7, 2026 /Business Wire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year-over-year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also outlined progress across four strategic priorities that it believes underpin long-term shareholder value.

“Harmony is well positioned for long-term growth, and we are focused on four key pillars to drive value creation. First, protect the pitolisant franchise to ensure durability into the 2030s, supported by multi-layered intellectual property. Second, continued growth of the pitolisant franchise in an evolving market by advancing new formulations and differentiated approaches to solidify our leadership in the sleep/wake market. Third, drive value from our pipeline, led by BP-205, which has the potential to be a highly differentiated and best-in-class orexin-2 agonist across multiple indications. And fourth, a renewed emphasis on business development with a goal to transact on opportunities with revenue potential in the 2028–2032 timeframe,” said Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. “Executing on these four pillars positions us well to deliver innovative treatments for patients and generate long-term value for shareholders.”

Key Pillars of Value Creation:

Protect the Pitolisant Franchise

● ANDA Settlements: 3 additional ANDA settlements were reached in Q1, bringing the total settlements to 6 of the 7 ANDA filers

● Acquired New IP: Acquired exclusive license to an issued patent out to 2042 for a novel amorphous form of pitolisant, providing Harmony with new development opportunities in broader CNS patient populations

● Strong IP protection/exclusivity: Harmony’s pitolisant IP estate is multi-layered (formulations, methods of use, next-gen applications) and supports WAKIX exclusivity into 2030 (inclusive of 6-months of pediatric exclusivity), with potential protection of the franchise into the 2040’s via additional patents/applications

● Filed Lawsuit: Harmony Biosciences and Novitium filed a patent infringement lawsuit in April against AET Pharma US and Sandoz, alleging infringement of patents covering an amorphous form of pitolisant hydrochloride

Continued Pitolisant Franchise Growth in an Evolving Market

First Quarter 2026 Net Product Revenue for WAKIX

● Net product revenue for the quarter ended March 31, 2026, was $215.4 million, compared to $184.7 million for the same period in 2025

o Average number of patients in Q1 was 8,500; exited the quarter with 8,600 average patients

On track to achieve >$1 Billion in narcolepsy net sales in 2026

● Net revenue projected between $1.0 billion to $1.04 billion for the full year ending December 31, 2026

● Received FDA approval of pediatric cataplexy indication on February 13th

o Commercial team initiated full promotional efforts immediately upon approval

● Pitolisant in Prader-Willi syndrome (PWS)

o Phase 3 topline data readout expected in 2H 2026

o Supports Pediatric Exclusivity for WAKIX: Fulfills a key regulatory requirement for six months of additional regulatory exclusivity, extending exclusivity to March 2030

Pitolisant GR (gastro-resistant): On track to extend pitolisant franchise into the 2040s

● NDA submission on track for Q2 2026; anticipated PDUFA date in Q1 2027

o Approximately 80-90% of patients with narcolepsy experience GI symptoms as part of their disease

o Pitolisant GR is designed with enteric coating meant to reduce the potential for GI side effects in patients prone to GI symptoms

o Enables patients to initiate treatment at a therapeutic dose without titration, an important clinical differentiation

● Utility patents filed to extend franchise into the 2040s

Pitolisant HD (high dose): Opportunity to expand pitolisant franchise with differentiated labeling

● Phase 3 registrational clinical trials ongoing in narcolepsy (ONSTRIDE 1) and idiopathic hypersomnia (IH) (ONSTRIDE 2)

o Topline data expected in 2027; anticipated PDUFA date in 2028

o Enhanced formulation with optimized PK profile, enteric coating and higher dose to drive greater efficacy

o Differentiated labeling: fatigue in narcolepsy and sleep inertia in IH

● Utility patents filed to expand franchise into the 2040s

Exploring novel amorphous form of pitolisant to pursue broader CNS indications

● This opportunity is based on the exclusive license to Novitium’s issued amorphous pitolisant patent with protection until 2042

● Current efforts focused on formulation optimization and new modes of delivery in preparation for Phase 1 PK study

Drive Value from our Robust Pipeline

Orexin-2 receptor agonist BP-205 (BP1.15205)

● BP-205 is Harmony’s lead OX2R agonist, built upon a novel chemical scaffold, with the potential for best-in-class therapy:

o The most potent OX2R agonist currently in clinical development

o The high potency enables the potential for significantly lower dosing than current OX2R assets under development

▪ Potential for once-daily dosing across NT1, NT2 and IH (supported by favorable preclinical PK profile)

o High selectivity for OX2R over OX1R and across 150 other receptors of interest

▪ Potential for favorable safety/tolerability profile (supported by preclinical safety pharmacology and toxicology data)

● Phase 1 SAD/MAD clinical study ongoing in Europe; on track for clinical PK, safety, and tolerability data from SAD phase in mid-2026

● U.S. IND submission planned for mid-2026

● Plan to initiate Phase 1b study in sleep-deprived healthy volunteers in 2H 2026

● Exploring use outside of sleep/wake, including cognition, ADHD, mood, and fatigue

EPX-100 (clemizole hydrochloride)

● One of the most advanced development programs in the 5HT2 (serotonin) agonist class

● Actively enrolling in two Global Phase 3 registrational trials in rare epilepsies:

o Lennox-Gastaut syndrome – the LIGHTHOUSE Study

o Dravet syndrome (DS) – the ARGUS Study

◾ Encore safety and effectiveness data from the open-label extension study in DS that showed clinically meaningful reduction in seizures and a favorable safety and tolerability profile was presented at AAN meeting in April 2026

◾ Both trials are currently enrolling in North America, Europe, China and India

● Topline data anticipated in 1H 2027 and potential PDUFA date in 2028

Renewed Emphasis on Business Development

● Focused on opportunities with revenue potential in 2028–2032

● Prioritizing assets in Phase 3, in-registration, or on-market

● Therapeutic areas of interest include Sleep/Wake, Epilepsy, Rare/Orphan CNS, and CNS adjacencies beyond rare disease

● Supported by a strong balance sheet and clear conviction to execute on strategic business development opportunities

● Strong liquidity position of $870.5 million in cash, cash equivalents, and investments as of March 31, 2026

Personnel Updates

● Appointed Peter Anastasiou as Chief Operating Officer (effective April 2, 2026) and Glenn Reicin as Chief Financial Officer (effective April 14, 2026), supporting continued focus on strategic growth

First Quarter 2026 Financial Results

Harmony Biosciences reported net product revenue of $215.4 million for the quarter ended March 31, 2026, compared to $184.7 million for the same period in 2025, representing 17% year-over-year growth. This performance reflects both continued demand for WAKIX within the large narcolepsy market opportunity (approximately 80,000 diagnosed patients in the U.S.) and the product's broad clinical utility. The continued success has been driven by strong execution across the organization from sales effectiveness to marketing and promotion and supported by broad payer coverage and how the company supports patients over time.

Cost of product sold was $44.5 million in the first quarter of 2026, or 20.7% as a percentage of net product revenue, as compared to $32.0 million, or 17.3%, for the same quarter in 2025, representing a 39% increase. The increase in cost of product sold as a percentage of net product revenue was driven by new royalties related to the Novitium license agreement.

Net income for the quarter was $32.5 million, or $0.55 per diluted share, compared to $45.6 million, or $0.78 per diluted share, in Q1 2025. The decline in earnings was entirely driven by the licensing agreements entered into during Q1 2026.

Harmony’s operating expenses include the following:

● Research and Development expenses were $69.4 million in the first quarter of 2026, as compared to $34.5 million for the same quarter in 2025, representing a 101% increase; the increase was primarily driven by $32.0 million in expenses related to up-front payments for license agreements that were entered into during Q1 2026, providing new development opportunities, which had an after-tax impact to earnings of $0.45 per share

● Sales and Marketing expenses were $31.7 million in the first quarter of 2026, as compared to $30.7 million for the same quarter in 2025, representing a 3% increase

● General and Administrative expenses were $32.5 million in the first quarter of 2026, as compared to $31.2 million for the same quarter in 2025, representing a 4% increase

● Total Operating Expenses were $133.6 million in the first quarter of 2026, as compared to $96.5 million for the same quarter in 2025, representing a 38% increase

As of March 31, 2026, Harmony had cash, cash equivalents and investments of $870.5 million, compared to $882.5 million as of December 31, 2025. The reduction was primarily due to up-front payments for license agreements and payment of ANDA settlements during Q1 2026.

2026 Net Product Revenue Guidance

Reiterated 2026 WAKIX Net Revenue Guidance of $1.0 Billion – $1.04 Billion

Conference Call Today at 8:30 a.m. ET

Harmony is hosting its first quarter 2026 financial results conference call and webcast today, beginning at 8:30 a.m. Eastern time. The live and replay webcast of the call will be available on the investor relations page of our website https://ir.harmonybiosciences.com/.

To participate in the live call by phone, dial: (888) 596-4144 (domestic) or (646) 968-2525 (international, alternate); reference passcode 6626692

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities

that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, plans to submit an sNDA for pitolisant in idiopathic hypersomnia; plans to submit an NDA for Pitolisant GR; plans to submit an IND for BP-205; our future results of operations and financial position, business strategy, products, prospective products, product approvals, the plans and objectives of management for future operations and future results of anticipated products. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved, including EPX-100, Pitolisant GT and BP-205; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreements with Bioprojet Société Civile de Recherche (“Bioprojet”); the availability of favorable insurance coverage and reimbursement for WAKIX; the timing of, and our ability to obtain, regulatory approvals for pitolisant for other indications as well as any other product candidates; our estimates regarding expenses, future revenue, capital requirements and additional financing needs; our ability to identify, acquire and integrate additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; statements related to our intended share repurchases and repurchase timeframe; and macroeconomic effects and changes in market conditions, including the impact of tariffs, inflation and the risk of recession. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-

looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(In thousands, except share and per share data)

Three Months Ended March 31,

2026

2025

Net product revenue

215,387

184,733

Cost of product sold

44,512

31,994

Gross profit

170,875

152,739

Operating expenses:

Research and development

69,383

34,540

Sales and marketing

31,694

30,711

General and administrative

32,507

31,243

Total operating expenses

133,584

96,494

Operating income

37,291

56,245

Other (expense) income, net

(127)

(276)

Interest expense

(3,234)

(3,836)

Interest income

5,757

5,044

Income before income taxes

39,687

57,177

Income tax expense

(7,199)

(11,617)

Net income

32,488

45,560

Unrealized (loss) income on investments

(759)

179

Comprehensive income

31,729

45,739

EARNINGS PER SHARE:

Basic

0.56

0.79

Diluted

0.55

0.78

Weighted average number of shares of common stock - basic

57,819,060

57,309,938

Weighted average number of shares of common stock - diluted

58,776,297

58,524,566

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

March 31,

December 31,

2026

2025

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

589,398

752,502

Investments, short-term

51,520

22,838

Trade receivables, net

108,222

96,787

Inventory, net

5,281

5,357

Prepaid expenses

16,801

16,014

Other current assets

7,595

13,516

Total current assets

778,817

907,014

NONCURRENT ASSETS:

Investments, long-term

229,555

107,127

Intangible assets, net

83,457

89,418

Deferred tax asset

153,562

149,699

Other noncurrent assets

26,433

18,373

Total noncurrent assets

493,007

364,617

TOTAL ASSETS

1,271,824

1,271,631

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:

Trade payables

28,600

17,693

Accrued compensation

6,726

18,443

Accrued expenses

150,107

191,039

Current portion of long-term debt

20,000

Other current liabilities

11,907

4,957

Total current liabilities

217,340

252,132

NONCURRENT LIABILITIES:

Long-term debt, net

138,814

143,663

Other noncurrent liabilities

5,321

5,618

Total noncurrent liabilities

144,135

149,281

TOTAL LIABILITIES

361,475

401,413

COMMITMENTS AND CONTINGENCIES (Note 13)

STOCKHOLDERS’ EQUITY:

Common stock—$0.00001 par value; 500,000,000 shares authorized at March 31, 2026, and December 31, 2025, respectively; 57,867,389 and 57,726,170 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively

Additional paid in capital

717,370

708,968

Accumulated other comprehensive (loss) income

(413)

346

Retained earnings

193,391

160,903

TOTAL STOCKHOLDERS’ EQUITY

910,349

870,218

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

1,271,824

1,271,631

Harmony Biosciences Investor Contact:

Brennan Doyle

484-566-3685

bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact:

Cate McCanless

202-641-6086

cmccanless@harmonybiosciences.com

EX-99.2

Filename: hrmy-20260507xex99d2.htm · Sequence: 3

Q1 2026 Financial Results and Business Update

May 7, 2026

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements

contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements

regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, plans to submit an NDA for Pitolisant GR; plans to

submit an IND for BP-205; our future results of operations and financial position, business strategy, products, prospective products, product approvals,

the plans and objectives of management for future operations and future results of anticipated products. These statements are neither promises nor

guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or

achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements,

including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical

utility of pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved, including Pitolisant

GR, Pitolisant HD, BP-205, and EPX-100; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in

additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreements with Bioprojet Société Civile de

Recherche (“Bioprojet”); the availability of favorable insurance coverage and reimbursement for WAKIX; the timing of, and our ability to obtain,

regulatory approvals for pitolisant for other indications as well as any other product candidates; our estimates regarding expenses, future revenue,

capital requirements and additional financing needs; our ability to identify, acquire and integrate additional products or product candidates with

significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities

and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to

successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the

impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management

time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially;

statements related to our intended share repurchases and repurchase timeframe; and macroeconomic effects and changes in market conditions,

including the impact of tariffs, inflation and the risk of recession. These and other important factors discussed under the caption "Risk Factors" in our

Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026 and our other filings with the SEC

could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking

statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

PROFITABLE SELF-FUNDING BIOTECH

PROVEN COMMERCIAL

ENGINE

STRONG BALANCE

SHEET

ROBUST PIPELINE

Moving with Urgency

on BD to Generate the

Next Wave of Growth

RENEWED

EMPHASIS

ON BUSINESS

DEVELOPMENT

Led by our OX2R in the

clinic, BP 205, potentially

best-in-class

5 Phase 3 registrational

trials in 5 distinct rare

CNS indications

ADVANCING

ROBUST

PIPELINE

BEYOND PITOLISANT

LIFECYCLE

MANAGEMENT

Advancing new

formulations and

differentiated approaches

CONTINUED

PITOLISANT

FRANCHISE

GROWTH

IN AN EVOLVING

MARKET

GROWING ADVANCING TRANSACTING

PILLARS OF VALUE CREATION

PROTECTING

PROTECT THE

PITOLISANT

FRANCHISE

Exclusivity into 2030s,

supported by multi-layered intellectual

property

Moving with Urgency

on BD to Generate the

Next Wave of Growth

RENEWED

EMPHASIS

ON BUSINESS

DEVELOPMENT

Led by our OX2R in the

clinic, BP 205, potentially

best-in-class

5 Phase 3 registrational

trials in 5 distinct rare

CNS indications

ADVANCING

ROBUST

PIPELINE

BEYOND PITOLISANT

LIFECYCLE

MANAGEMENT

Advancing new

formulations and

differentiated approaches

CONTINUED

PITOLISANT

FRANCHISE

GROWTH

IN AN EVOLVING

MARKET

Exclusivity into 2030s,

supported by multi-layered

intellectual property

PROTECT THE

PITOLISANT

FRANCHISE

PROTECTING GROWING ADVANCING TRANSACTING

PILLARS OF VALUE CREATION

Protect the Pitolisant Franchise

WAKIX

LOE INTO 2030

WITH PEDIATRIC

EXCLUSIVITY

PROTECTING GROWING ADVANCING TRANSACTING

STRONG IP PROTECTION

Multi-layered IP estate – formulation, methods of use, next-gen applications

6-MONTH PEDIATRIC EXCLUSIVITY

On track with PWS Phase 3 data 2H 2026

UTILITY PATENTS FILED FOR NEXT GEN PITOLISANT

FORMULATIONS

Potential protection into the 2040s

LICENSE TO NOVEL AMORPHOUS FORM OF PITOLISANT

New development opportunity in broader CNS patient populations

SETTLEMENTS WITH 6 OF 7 ANDA FILERS

Maintaining LOE until March of 2030, inclusive of 6-months of pediatric exclusivity

NEW LAWSUIT FILED

Harmony and Novitium filed patent infringement lawsuit against AET US and Sandoz

alleging infringement of a patent covering amorphous form of pitolisant hydrochloride

Moving with Urgency

on BD to Generate the

Next Wave of Growth

RENEWED

EMPHASIS

ON BUSINESS

DEVELOPMENT

Led by our OX2R in the

clinic, BP 205, potentially

best-in-class

5 Phase 3 registrational

trials in 5 distinct rare

CNS indications

ADVANCING

ROBUST

PIPELINE

BEYOND PITOLISANT

LIFECYCLE

MANAGEMENT

Advancing new

formulations and

differentiated approaches

CONTINUED

PITOLISANT

FRANCHISE

GROWTH

IN AN EVOLVING

MARKET

Exclusivity into 2030s,

supported by multi-layered

intellectual property

PROTECT THE

PITOLISANT

FRANCHISE

PROTECTING GROWING ADVANCING TRANSACTING

PILLARS OF VALUE CREATION

Continued Pitolisant Franchise Growth in an Evolving Market

PROTECTING GROWING TRANSACTING

CONTINUE TO LEAD WITH WAKIX: ON TRACK FOR >$1B

NET REVENUE IN 2026

PITOLISANT GR – NDA SUBMISSION 2Q26, PDUFA DATE

ANTICIPATED IN Q1 2027

Positioned to extend the WAKIX franchise with broad clinical utility

PITOLISANT HD – 2 ONGOING PHASE 3 REGISTRATIONAL

STUDIES WITH TLD EXPECTED IN 2027

To grow pitolisant franchise and extend leadership position in Sleep/Wake

NOVEL AMORPHOUS FORM OF PITOLISANT – BROADER

CNS INDICATIONS AND PATENT PROTECTION TO 2042

Current efforts focused on formulation optimization and new modes of delivery in

preparation for phase 1 PK study

ADVANCING

GROW

EXTEND

EXPAND

Moving with Urgency

on BD to Generate the

Next Wave of Growth

RENEWED

EMPHASIS

ON BUSINESS

DEVELOPMENT

Led by our OX2R in the

clinic, BP 205, potentially

best-in-class

5 Phase 3 registrational

trials in 5 distinct rare

CNS indications

ADVANCING

ROBUST

PIPELINE

BEYOND PITOLISANT

LIFECYCLE

MANAGEMENT

Advancing new

formulations and

differentiated approaches

CONTINUED

PITOLISANT

FRANCHISE

GROWTH

IN AN EVOLVING

MARKET

Exclusivity into 2030s,

supported by multi-layered

intellectual property

PROTECT THE

PITOLISANT

FRANCHISE

PROTECTING GROWING ADVANCING TRANSACTING

PILLARS OF VALUE CREATION

Robust Pipeline Beyond Pitolisant Lifecycle Management

PRODUCT INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY FILING MARKETED PRODUCT

EDS in Narcolepsy (Adult/Pediatric*)

WAKIX®

Cataplexy in Narcolepsy (Adult/Pediatric*)

Pitolisant Gastro-Resistant (GR) in Narcolepsy

Pitolisant

Prader-Willi Syndrome (PWS)

Pitolisant High-Dose (HD) in Narcolepsy

Pitolisant High-Dose (HD) in Idiopathic Hypersomnia

Pitolisant High-Dose (HD) in Myotonic Dystrophy (DM1)

Pitolisant Amorphous Form

CBS105 Treatment-Resistant Narcolepsy

HBS-102 PWS

Dravet Syndrome (DS) EPX-100 (Clemizole

Hydrochloride Lennox-Gastaut Syndrome (LGS)

EPX-200 (Lorcaserin) Developmental and Epileptic Encephalopathies

CBS104 Refractory Epilepsy

*Ages 6 years and older

Research collaboration with CiRC Biosciences..

Innovative Late-Stage Pipeline With Multiple Catalysts 2026–2028

PROTECTING GROWING ADVANCING TRANSACTING

BP-205 (Orexin-2

Receptor Agonist) Sleep/Wake Disorders

Moving with Urgency

on BD to Generate the

Next Wave of Growth

RENEWED

EMPHASIS

ON BUSINESS

DEVELOPMENT

Led by our OX2R in the

clinic, BP 205, potentially

best-in-class

5 Phase 3 registrational

trials in 5 distinct rare

CNS indications

ADVANCING

ROBUST

PIPELINE

BEYOND PITOLISANT

LIFECYCLE

MANAGEMENT

Advancing new

formulations and

differentiated approaches

CONTINUED

PITOLISANT

FRANCHISE

GROWTH

IN AN EVOLVING

MARKET

Exclusivity into 2030s,

supported by multi-layered

intellectual property

PROTECT THE

PITOLISANT

FRANCHISE

PROTECTING GROWING ADVANCING TRANSACTING

PILLARS OF VALUE CREATION

Renewed Emphasis on Business Development

PROTECTING GROWING TRANSACTING

SIGNIFICANT

CAPACITY TO

TRANSACT

RENEWED FOCUS ON BD OPPORTUNITIES WITH

EMPHASIS ON:

• Revenues in 2028-2032

• Assets in Phase 3, In-Registration, or On-Market

THERAPEUTIC AREAS OF INTEREST

• Sleep/Wake

• Epilepsy

• Rare/Orphan CNS

• CNS adjacencies beyond Rare/Orphan

STRONG BALANCE SHEET WITH ~ $870M IN CASH,

EQUIVALENTS

URGENCY & CONVICTION TO EXECUTE ON STRATEGIC

BD OPPORTUNITIES

ADVANCING

Moving with Urgency

on BD to Generate the

Next Wave of Growth

RENEWED

EMPHASIS

ON BUSINESS

DEVELOPMENT

Led by our OX2R in the

clinic, BP 205, potentially

best-in-class

5 Phase 3 registrational

trials in 5 distinct rare

CNS indications

ADVANCING

ROBUST

PIPELINE

BEYOND PITOLISANT

LIFECYCLE

MANAGEMENT

Advancing new

formulations and

differentiated approaches

CONTINUED

PITOLISANT

FRANCHISE

GROWTH

IN AN EVOLVING

MARKET

GROWING ADVANCING TRANSACTING

PILLARS OF VALUE CREATION

PROTECTING

PROTECT THE

PITOLISANT

FRANCHISE

Exclusivity into 2030s,

supported by multi-layered intellectual

property

Reiterating 2026 Net Revenue Guidance

$1.00B-$1.04B

2026 NET REVENUE GUIDANCE

WAKIX Net Revenue Growth 2020–2025

$160

$305

$438

$582

$715

$869

$1B+

$200

$400

$600

$800

$1,000

2020 2021 2022 2023 2024 2025 2026

Guidance

Net Revenue ($M)

PROTECTING GROWING TRANSACTING

On Track to Achieve $1B+ in Narcolepsy

ADVANCING

WAKIX® Differentiation and Strong Execution Drive Performance

1. https://narcolepsynetwork.org/accessed Feb 2024

• 17% Quarter over Quarter revenue growth: on track

to achieve $1B+ in 2026 net sales

• After 3 consecutive quarters of record growth:

adding ~400+ patients for the first time

• Strong demand despite seasonal headwinds

• March demand higher than nearly all months in 2025

• 8,600 exit patients in Q1: momentum into Q2

Average Patients on WAKIX

8,500

1,000

2,000

3,000

4,000

5,000

6,000

7,000

8,000

9,000

Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26

KEY

TAKEAWAY On Track To Achieve $1B+ in Net Sales

PROTECTING GROWING ADVANCING TRANSACTING

WAKIX Differentiation and Strong Execution Drive Performance

80,000

90,000 ~170,000

Diagnosed

Narcolepsy

Patients

Undiagnosed

Narcolepsy

Population

People Living With Narcolepsy in the U.S.1

90K+ Undiagnosed = 2× Today's Market

LARGE

MARKET

OPPORTUNITY

• ~170K total Narcolepsy

patients

• ~90K+ undiagnosed:

2X opportunity remains

• ~20% brand penetration:

in polypharmacy market

DIFFERENTIATED

PRODUCT

• Only non-scheduled treatment option

• 7+ years clinical experience

EXPANDED

TEAM

• ~20% expansion complete as of Apr 1

• Largest expansion in brand history

BROAD PAYER

ACCESS

• 80% lives covered

• Expanded access in 2025

GR & HD LCM

PROGRAMS

• Differentiated products meet unmet

patient needs to fuel continued growth

PROTECTING GROWING ADVANCING TRANSACTING

KEY

TAKEAWAY Significant Growth Potential Remains

Robust Pipeline Beyond Pitolisant Lifecycle Management

PRODUCT INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY FILING MARKETED PRODUCT

EDS in Narcolepsy (Adult/Pediatric*)

WAKIX®

Cataplexy in Narcolepsy (Adult/Pediatric*)

Pitolisant Gastro-Resistant (GR) in Narcolepsy

Pitolisant

Prader-Willi Syndrome (PWS)

Pitolisant High-Dose (HD) in Narcolepsy

Pitolisant High-Dose (HD) in Idiopathic Hypersomnia

Pitolisant High-Dose (HD) in Myotonic Dystrophy (DM1)

Pitolisant Amorphous Form

Sleep/Wake Disorders BP-205 (Orexin-2 Receptor Agonist)

CBS105 Treatment-Resistant Narcolepsy

HBS-102 PWS

Dravet Syndrome (DS) EPX-100 (Clemizole

Hydrochloride Lennox-Gastaut Syndrome (LGS)

EPX-200 (Lorcaserin) Developmental and Epileptic Encephalopathies

CBS104 Refractory Epilepsy

*Ages 6 years and older

Research collaboration with CiRC Biosciences..

Innovative Late-Stage Pipeline With Multiple Catalysts 2026–2028

PROTECTING GROWING ADVANCING TRANSACTING

BP-205: Potential for Best-in-Class OX2R Agonist

BUILT ON NOVEL CHEMICAL SCAFFOLD

Leads to differentiated product profile

HIGH POTENCY

Enables the potential for significantly lower dosing and target all 3 central disorders of hypersomnolence,

NT1, NT2 and IH

HIGH SELECTIVITY

For OX2R over OX1R and 150 other receptors of interest

FAVORABLE SAFETY/TOLERABILITY PROFILE

Supported by preclinical safety pharmacology and toxicology data

PHASE 1 SAD/MAD CLINICAL STUDY ONGOING IN EUROPE

SAD clinical PK, safety, and tolerability data in mid-2026

U.S. IND SUBMISSION PLANNED FOR MID-2026

PLAN TO INITIATE PH 1B IN STUDY IN SLEEP-DEPRIVED HEALTHY

VOLUNTEERS IN 2H26

EXPLORING USE OUTSIDE OF SLEEP/WAKE

Preclinical experiments in broader neuropsych indications targeting mood, ADHD, cognition, and fatigue.

PROTECTING GROWING TRANSACTING

MOST

POTENT

OX2R IN

CLINIC

ADVANCING

Pitolisant GR (Gastro-Resistant):

On Track To Extend Pitolisant Franchise Into 2040’s

PROTECTING TRANSACTING

Q1 2027

ANTICIPATED

PDUFA DATE

NDA SUBMISSION ON TRACK FOR Q2 2026

Anticipated PDUFA date in Q1 2027

APPROXIMATELY 80-90% OF PATIENTS WITH

NARCOLEPSY EXPERIENCE GI SYMPTOMS AS PART OF

THEIR DISEASE

PITOLISANT GR IS DESIGNED WITH ENTERIC COATING

Meant to reduce the potential for GI side effects in patients prone to GI

symptoms

ALLOWS PATIENTS TO INITIATE TREATMENT AT A

THERAPEUTIC DOSE WITHOUT TITRATION

An important clinical differentiation

UTILITY PATENTS FILED TO EXTEND FRANCHISE INTO

THE 2040s

GROWING ADVANCING VALUE

Pitolisant HD:

Opportunity To Expand Pitolisant Franchise With Differentiated Labeling

PROTECTING TRANSACTING

2027

ANTICIPATED PHASE 3

TOPLINE DATA

PHASE 3 REGISTRATIONAL CLINICAL TRIALS ONGOING

TOPLINE DATA ANTICIPATED IN 2027

Target PDUFA date in 2028

ENHANCED FORMULATION WITH OPTIMIZED PK PROFILE

Enteric coating and higher dose to drive greater efficacy

DIFFERENTIATED LABELING

Fatigue in narcolepsy and sleep inertia in IH

UTILITY PATENTS FILED TO EXTEND FRANCHISE INTO

THE 2040s

GROWING ADVANCING

Robust Pipeline Beyond Pitolisant Lifecycle Management

PRODUCT INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 REGULATORY FILING MARKETED PRODUCT

EDS in Narcolepsy (Adult/Pediatric*)

WAKIX®

Cataplexy in Narcolepsy (Adult/Pediatric*)

Pitolisant Gastro-Resistant (GR) in Narcolepsy

Pitolisant

Pitolisant High-Dose (HD) in Narcolepsy

Pitolisant High-Dose (HD) in Idiopathic Hypersomnia

Pitolisant High-Dose (HD) in Myotonic Dystrophy (DM1)

Sleep/Wake Disorders BP205 (Orexin-2 Receptor Agonist)

CBS105 Treatment-Resistant Narcolepsy

HBS-102 PWS

Dravet Syndrome (DS) EPX-100 (Clemizole

Hydrochloride Lennox-Gastaut Syndrome (LGS)

EPX-200 (Lorcaserin) Developmental and Epileptic Encephalopathies

CBS104 Refractory Epilepsy

*Ages 6 years and older

Research collaboration with CiRC Biosciences..

Innovative Late-Stage Pipeline With Multiple Catalysts 2026–2028

PROTECTING GROWING ADVANCING TRANSACTING

Prader-Willi Syndrome (PWS)

Pitolisant Amorphous Form

ADVANCING

EPX-100: One of Most Advanced 5-HT2 (Serotonin) Agonist Programs in DEEs

ESTABLISHED 5-HT2 (SEROTONIN) AGONIST

MECHANISM OF ACTION

ONGOING PHASE 3 TRIALS IN LENNOX-GASTAUT

SYNDROME (LIGHTHOUSE) & DRAVET SYNDROME

(ARGUS)

Topline data anticipated 1H 2027

SAFETY: POTENTIAL TO OFFER A UNIQUE RISK/BENEFIT

PROPOSITION

No additional laboratory or special safety monitoring

BID DOSING REGIMEN

Convenient for patients and caregivers

PROTECTING GROWING DRIVING VALUE TRANSACTING

Median reduction of ~50% in

countable motor seizure frequency

per 28 days (CMS-28) in

participants who had at least 6-

month exposure to EPX-100;

at least 50% reduction in CMS-28

in 50% of these participants

ADVANCING

2027

ANTICIPATED PHASE 3

TOPLINE DATA

Financial Summary Q1 2026

• $32 million in

expenses related to

up-front payments for

amorphous license

agreements impacted

diluted EPS by $0.45 a

share after taxes.

• Cash generation was

muted in the quarter

due to up-front license

fee payments,

payments for ANDA

settlements announced

last quarter and a

seasonal reduction in

accrued expenses.

$184.7 $215.4

Q1 2025 Q1 2026

$610.2 $672.3 $778.4 $882.5 $870.5

Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026

Three Months Ended

March 31, 2026

(In millions, USD)

Net Product

Revenue

Diluted

Earnings per

Cash, Cash

Equivalents

Investments

-29%

17%

-$12M

Three Months Ended

March 31, 2026

$0.78

$0.55

Q1 2025 Q1 2026

Inclusive of -$0.45 per

share related to new

license agreements

PROTECTING GROWING ADVANCING TRANSACTING

Financial Summary Q1 2026

•Cost of Product Sold as a

percentage of Net Product

Revenue increased due to

new royalties related to

Novitium License

Agreement.

•R&D Expense includes

$32 million in IPR&D

charges related to

amorphous license

agreements entered in Q1

2026

•Operating Expenses

would have increased a

modest 5% without IPR&D

charges.

% Change

Three Months Ended

March 31,

Totals may not foot due to rounding 2026 2025

Net Product Revenue $215.4 $184.7 17%

Cost of Product Sold 44.5 32.0 39%

Total Operating Expenses $133.6 $96.5 38%

R&D Expense 69.4 34.5 101%

S&M Expense 31.7 30.7 3%

G&A Expense 32.5 31.2 4%

Net Income $32.5 $45.6 -29%

Cash, cash equivalents & investments $870.5 $610.2 43%

(In millions, USD)

PROTECTING GROWING ADVANCING TRANSACTING

EMPHASIS

ON BUSINESS

DEVELOPMENT

ADVANCING

ROBUST

PIPELINE

BEYOND PITOLISANT

LIFECYCLE

MANAGEMENT

CONTINUED

PITOLISANT

FRANCHISE

GROWTH

IN AN EVOLVING

MARKET

PROTECT THE

PITOLISANT

FRANCHISE

PROTECTING GROWING ADVANCING TRANSACTING

Well-positioned to deliver innovative treatments to patients

while driving sustained long-term value for shareholders

PILLARS OF VALUE CREATION

company/harmonybiosciences/ @harmonybio harmony_biosciences

www.harmonybiosciences.com

GRAPHIC

Filename: hrmy-20260507x8k001.jpg · Sequence: 4

Binary file (1167 bytes)

Download hrmy-20260507x8k001.jpg

GRAPHIC

Filename: hrmy-20260507xex99d1001.jpg · Sequence: 5

Binary file (10845 bytes)

Download hrmy-20260507xex99d1001.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g001.jpg · Sequence: 6

Binary file (119395 bytes)

Download hrmy-20260507xex99d2g001.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g002.jpg · Sequence: 7

Binary file (307153 bytes)

Download hrmy-20260507xex99d2g002.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g003.jpg · Sequence: 8

Binary file (108300 bytes)

Download hrmy-20260507xex99d2g003.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g004.jpg · Sequence: 9

Binary file (137737 bytes)

Download hrmy-20260507xex99d2g004.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g005.jpg · Sequence: 10

Binary file (138801 bytes)

Download hrmy-20260507xex99d2g005.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g006.jpg · Sequence: 11

Binary file (119378 bytes)

Download hrmy-20260507xex99d2g006.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g007.jpg · Sequence: 12

Binary file (138885 bytes)

Download hrmy-20260507xex99d2g007.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g008.jpg · Sequence: 13

Binary file (138517 bytes)

Download hrmy-20260507xex99d2g008.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g009.jpg · Sequence: 14

Binary file (137264 bytes)

Download hrmy-20260507xex99d2g009.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g010.jpg · Sequence: 15

Binary file (133026 bytes)

Download hrmy-20260507xex99d2g010.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g011.jpg · Sequence: 16

Binary file (140257 bytes)

Download hrmy-20260507xex99d2g011.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g012.jpg · Sequence: 17

Binary file (112546 bytes)

Download hrmy-20260507xex99d2g012.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g013.jpg · Sequence: 18

Binary file (137737 bytes)

Download hrmy-20260507xex99d2g013.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g014.jpg · Sequence: 19

Binary file (121753 bytes)

Download hrmy-20260507xex99d2g014.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g015.jpg · Sequence: 20

Binary file (125240 bytes)

Download hrmy-20260507xex99d2g015.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g016.jpg · Sequence: 21

Binary file (131417 bytes)

Download hrmy-20260507xex99d2g016.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g017.jpg · Sequence: 22

Binary file (131150 bytes)

Download hrmy-20260507xex99d2g017.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g018.jpg · Sequence: 23

Binary file (128765 bytes)

Download hrmy-20260507xex99d2g018.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g019.jpg · Sequence: 24

Binary file (131599 bytes)

Download hrmy-20260507xex99d2g019.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g020.jpg · Sequence: 25

Binary file (118149 bytes)

Download hrmy-20260507xex99d2g020.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g021.jpg · Sequence: 26

Binary file (136507 bytes)

Download hrmy-20260507xex99d2g021.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g022.jpg · Sequence: 27

Binary file (136285 bytes)

Download hrmy-20260507xex99d2g022.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g023.jpg · Sequence: 28

Binary file (126626 bytes)

Download hrmy-20260507xex99d2g023.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g024.jpg · Sequence: 29

Binary file (126257 bytes)

Download hrmy-20260507xex99d2g024.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g025.jpg · Sequence: 30

Binary file (141247 bytes)

Download hrmy-20260507xex99d2g025.jpg

GRAPHIC

Filename: hrmy-20260507xex99d2g026.jpg · Sequence: 31

Binary file (148134 bytes)

Download hrmy-20260507xex99d2g026.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 36

v3.26.1

Document and Entity Information

May 07, 2026

Document and Entity Information [Abstract]

Amendment Flag

false

Entity Central Index Key

0001802665

Document Type

8-K

Document Period End Date

May 07, 2026

Entity File Number

001-39450

Entity Registrant Name

HARMONY BIOSCIENCES HOLDINGS, INC.

Entity Incorporation, State or Country Code

Entity Tax Identification Number

82-2279923

Entity Address, Address Line One

630 W. Germantown Pike

Entity Address, Adress Line Two

Suite 215

Entity Address, City or Town

Plymouth Meeting

Entity Address, State or Province

Entity Address, Postal Zip Code

19462

City Area Code

484

Local Phone Number

539-9800

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.00001 par value per share

Trading Symbol

HRMY

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration